Literature DB >> 11113241

Increased levels of plasma malondialdehyde in Friedreich ataxia.

M Emond1, G Lepage, M Vanasse, M Pandolfo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11113241     DOI： 10.1212/wnl.55.11.1752

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  59 in total

1.  Antioxidant enzymes in blood of patients with Friedreich's ataxia.

Authors:  G Tozzi; M Nuccetelli; M Lo Bello; S Bernardini; L Bellincampi; S Ballerini; L M Gaeta; C Casali; A Pastore; G Federici; E Bertini; F Piemonte
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

2.  Defects in mitochondrial axonal transport and membrane potential without increased reactive oxygen species production in a Drosophila model of Friedreich ataxia.

Authors:  Yujiro Shidara; Peter J Hollenbeck
Journal:  J Neurosci       Date:  2010-08-25       Impact factor: 6.167

Review 3.  Some observations upon biochemical causes of ataxia and a new disease entity ubiquinone, CoQ10 deficiency.

Authors:  John M Land; Simon J R Heales; Andrew J Duncan; Iain P Hargreaves
Journal:  Neurochem Res       Date:  2006-12-21       Impact factor: 3.996

4.  PEP-1-frataxin significantly increases cell proliferation and neuroblast differentiation by reducing lipid peroxidation in the mouse dentate gyrus.

Authors:  Woosuk Kim; Dae Won Kim; Bich Na Shin; Dae Young Yoo; Sung Min Nam; Mi Jin Kim; Jung Hoon Choi; Yeo Sung Yoon; Moo-Ho Won; Soo Young Choi; In Koo Hwang
Journal:  Neurochem Res       Date:  2011-09-01       Impact factor: 3.996

Review 5.  Pharmacological treatments for Friedreich ataxia.

Authors:  Mary Kearney; Richard W Orrell; Michael Fahey; Ruth Brassington; Massimo Pandolfo
Journal:  Cochrane Database Syst Rev       Date:  2016-08-30

6.  Protective effects of Fe-Aox29, a novel antioxidant derived from a molecular combination of Idebenone and vitamin E, in immortalized fibroblasts and fibroblasts from patients with Friedreich Ataxia.

Authors:  Matthias L Jauslin; Silvia Vertuani; Elisa Durini; Lisa Buzzoni; Nunzia Ciliberti; Sara Verdecchia; Paola Palozza; Thomas Meier; Stefano Manfredini
Journal:  Mol Cell Biochem       Date:  2007-05-03       Impact factor: 3.396

Review 7.  Therapeutic strategies in Friedreich's ataxia.

Authors:  Timothy E Richardson; Heather N Kelly; Amanda E Yu; James W Simpkins
Journal:  Brain Res       Date:  2013-04-13       Impact factor: 3.252

8.  PGC-1alpha down-regulation affects the antioxidant response in Friedreich's ataxia.

Authors:  Daniele Marmolino; Mario Manto; Fabio Acquaviva; Paola Vergara; Ajay Ravella; Antonella Monticelli; Massimo Pandolfo
Journal:  PLoS One       Date:  2010-04-07       Impact factor: 3.240

9.  Limitations in a frataxin knockdown cell model for Friedreich ataxia in a high-throughput drug screen.

Authors:  Nadège Calmels; Hervé Seznec; Pascal Villa; Laurence Reutenauer; Marcel Hibert; Jacques Haiech; Pierre Rustin; Michel Koenig; Hélène Puccio
Journal:  BMC Neurol       Date:  2009-08-24       Impact factor: 2.474

10.  Altered gene expression and DNA damage in peripheral blood cells from Friedreich's ataxia patients: cellular model of pathology.

Authors:  Astrid C Haugen; Nicholas A Di Prospero; Joel S Parker; Rick D Fannin; Jeff Chou; Joel N Meyer; Christopher Halweg; Jennifer B Collins; Alexandra Durr; Kenneth Fischbeck; Bennett Van Houten
Journal:  PLoS Genet       Date:  2010-01-15       Impact factor: 5.917
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.